Loading
Ribociclib is the CDK4/6 inhibitor with the most consistent survival benefit, approved for a broad population of early breast cancer patients since 2024.
Ribociclib is a CDK4-biased CDK4/6 inhibitor given for 21 days of a 28-day cycle with an aromatase inhibitor or fulvestrant, at 600 mg daily in advanced disease or 400 mg daily for 3 years in the adjuvant setting. Its survival data are the most consistent in the class: MONALEESA-2, -3 and -7 each showed an overall survival benefit in HR-positive, HER2-negative advanced breast cancer, and NATALEE extended it to stage II-III early disease, including node-negative tumours, with an invasive disease-free survival HR of 0.75 (4-year iDFS 88.5% versus 83.6%), leading to adjuvant approval in September 2024. Novartis markets it. Neutropenia is near-universal (94%), and QT and liver enzymes need monitoring. Whether the adjuvant benefit matures into a survival gain remains open. For a newcomer: the CDK4/6 pill with the broadest proven benefit in hormone-driven breast cancer.
CDK4-biased CDK4/6 inhibitor. Connects to CDK4/6.
1.Oral drug is absorbed and reaches the tumour
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Some PBMs designate a preferred CDK4/6 inhibitor.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA496 · SMC advice: ribociclib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
With aromatase inhibitor, HR+/HER2- advanced breast cancer (MONALEESA-2) source
Pre/perimenopausal women and with fulvestrant (MONALEESA-7/-3) source
Adjuvant stage II-III HR+/HER2- early breast cancer at high risk (NATALEE) source
| Region | Year | Indication |
|---|---|---|
| US | 2017 | HR+/HER2- advanced breast cancer |
| US | 2024 | Adjuvant stage II-III HR+/HER2- breast cancer at high risk of recurrence |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutrophils decreased NATALEE / MONALEESA-2 | 94% | 45% |
| Leukocytes decreased NATALEE / MONALEESA-2 | 95% | - |
| Lymphocytes decreased NATALEE / MONALEESA-2 | 97% | - |
| Infections NATALEE / MONALEESA-2 | 37% | - |
| ALT/AST increased (grade 3-4) 8-11% across trials | - | 8% |
| Nausea NATALEE / MONALEESA-2 | - | - |
| Fatigue NATALEE / MONALEESA-2 | - | - |
| Diarrhoea NATALEE / MONALEESA-2 | - | - |
| QT prolongation Concentration-dependent; ECG monitoring required | - | - |
Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (cdk4/6 inhibitors) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part D (oral); commercial plans per formulary, often with prior authorisation | not disclosed | novartis.com/us-en/patient-support |
| United Kingdom | NICE: recommended with aromatase inhibitor (TA496), fulvestrant (TA687), and adjuvant (2025) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ribociclib" OR ABSTRACT:"Ribociclib" OR TITLE:"Kisqali" OR ABSTRACT:"Kisqali" OR TITLE:"Ribociclib Succinate and Letrozole" OR ABSTRACT:"Ribociclib Succinate and Letrozole" OR TITLE:"Kisqali Femara Co-Pack" OR ABSTRACT:"Kisqali Femara Co-Pack") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ribociclib, not a curated reading list.
Shares A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC, A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With , Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease, A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer).
Shares A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC, A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With , Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease, A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer).
Shares Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors, A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer), First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors, Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2).
Shares Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease, CDK4-selective inhibitors as the new first-line backbone, The cell-cycle engine (cyclins & CDKs), CDK4/6.
Shares A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With , A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer, Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer, Breast cancer (KEGG map).
Shares Study of AVZO-021 in Patients With Advanced Solid Tumors, MONALEESA-2, ER status (oestrogen receptor by IHC), Invasive lobular carcinoma of the breast.
Shares A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer, A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer), A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer, High-risk early HR-positive breast cancer.
Shares Debu Tripathy, MONALEESA-2, Seock-Ah Im, ER status (oestrogen receptor by IHC).